George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
(i) to set current context and focus to the report, which is otherwise bias to 2023 and the 31/12/23 position and required disclosures; and
(ii) it's a continuation of the much improved and welcome engagement with shareholders (as a whole) that we started to see in 2023, and this is re-emphasised on page 31 of the Annual Report (but to save people reading teh report to find it):
"The Company is committed to a continuous dialogue with shareholders as it believes that this is essential to ensure a greater understanding of and confidence amongst its shareholders in the medium- and longer- term strategy of the Group and in the Board’s ability to oversee its implementation. It is the responsibility of the Board as a whole to ensure that a satisfactory dialogue takes place."
That said, (as many others have stated they have found previously) I also didn't get 'Proof of Concept' for the statement promulgated on p32 of the Annual Report:
"The Board’s primary shareholder contact is through Peter Redmond, the Non-Executive Director responsible for shareholder relations." - as I too didn't get any response or acknowledgement to my emailed request. But I see that he was in attendance at 12/12 board meetings in 2023 - though I'm not sure that's going to get my vote for re-election at this year's AGM - more needed.
With your critical thinking caps on... Why the interview now?
Well said Hikikomori.
I guess most of us will topslice some along the way.
Quite frankly, it would be downright silly not to de-risk a portion at some point.
But based on the fantastic information that was released yesterday, I intend on selling as few as I can defend.
As you say, if CBR delivers just a fraction.
Wow
But before then we got CAR-T, news will eventually come, question is will the investors who are willing to pay above today's share price follow?
If they don't, then the share price will stay suppressed, it's a simple question of supply and demand.
Even if the science is first class.
And from what was in the RNS yesterday, I can only conclude that the science is indeed first class.
And that the board is capable of getting funding in a difficult market.
There is a lot to like in my view.
Well I’ll still be here, perhaps with a few less shares, but I’ll definitely still hold a good few.
If CBR can deliver a fraction of what it promises it might, 1000% will seem like chicken feed.
I absolutely intend to make sure I’m still in the game to find out.
Have a good weekend all.
Well we will see how many of us are still with you when you get that uplift, but once again good luck.
I’m after the sharp rise, 1000%
Hulver - good post ,
Prevail ain’t no naive muppets , they are a professional organisation who backed Hemos science & tossed a wedge in a lot higher than current stock price ,
I’m sure Vlad & Prevail are investigating all potential avenues for the benefit of Hemo & stockholders including Prevail .
Noted by Prevail in Sept RNS
Mary Schaheen, President of Prevail Partners, stated: "Everyone at our fund is confident in the growth and success of Hemogenyx Pharmaceuticals as they develop CAR-T cells to target acute myeloid leukemia. Furthermore, Hemogenyx Pharmaceuticals has a seasoned management team with the expertise to accelerate the company to a significant value inflection point through the completion of its planned clinical trial."
Let’s see what next few months bring
The agreement was from Sept last year so unlikely that they knew the date they would commence given the FDA approval was still pending
An extract from Note 23 of the Financial Statements under Service Agreements:
"In September 2023, Hemogenyx Pharmaceuticals entered into a Master Services and Contract Agreement for a third party to provide clinical services and technologies for the forthcoming Phase I clinical trials for an initial term of 38 months, paying an aggregate of 2,530,057. This includes an upfront payment of 986,713 and monthly instalments over 38 months of 41,712 commencing in April 2024. No sums other than an upfront fee were paid during the year ended 31 December 2023."
- the monthly instalments payments 'commencing April 24' suggests to me that the commencement of the first trial is not that far away now, as Prevail are starting or about to start to undertake the regular work/services to be provided under the contract.
Hope it pays off for you,
Depends what your after I suppose but the slightest sniff of positive news and a sharp rise may provide you with an opportunity to get out with a profit..... or any other option you feel appropriate.
Good luck
Bit the bullet and bought in here this morning. Fingers crossed the gamble pays off
The company featured in this link like to invest in disruptive biotech CBR seems a perfect fit. Worth a call perhaps VS.
https://www.labiotech.eu/podcast/biotech-investment-landscape-2024/
Ssccs....I see you sold HEMO on 4th March 2022.The SP on tha date was 1.22p...I can see why yo are re so bitter...your posting history is gold.
You'd be better posting on stocks you own, not on ones you got shafted on and lost money not crying like a baby and trying to deramp.
Remember,nobody posts on a share they don't own with out a reason...we rtainly don't need your nuggets of shyte.
You'd be much better off channeling your energies towards Vlad rather than a random person in the forum whose posts you don't agree with. Plus I hope you do realise the sp is nothing to do with me?! Crazy person.
I have figured out you are trying your best to deramp this share and my investment you toerag...just do one.
You really haven't figured it out yet have you. Wow.
Why is it dull to post on your only investment???? Filter me if you want, but. Am now studying SYN and it looks really bleak there..10bn shares... crikey..
Hemotruth, I know you find it hard to understand but it doesn't bother me what you post where. Please go for it. Knock yourself out. Live a little. Must be dull to only post on hemo. You are more than welcome at syn.
Yup. It's a public forum, and I have now developed an interest in SYN...enjoy.
You actually posted on syn. You are a total numpty lol.
Just ignore me. Honestly, it's quite easy. I am allowed to post on this board. It's a public board. Filter me... Please
That's a rather large assumption you have made there Hulver. Obviously because it's pro hemo, it's allowed. What a joke this board is. None so blind as those who will not see.